NovelBeam Technology(SH:688677) Xin Lang Cai Jing·2025-08-04 08:00Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is experiencing significant growth in its medical device segment, particularly in high-performance endoscope products, benefiting from the depreciation of the RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise [2][3]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. Its main business involves the research, development, production, and sales of medical endoscope devices and optical products [7]. - The revenue composition of the company is as follows: 77.94% from medical endoscope devices, 21.55% from optical products, and 0.51% from other sources [7]. Financial Performance - For the first quarter of 2025, the company achieved a revenue of 147 million yuan, representing a year-on-year growth of 24.86%, and a net profit attributable to shareholders of 46.69 million yuan, up 21.45% year-on-year [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Market Position and Recognition - The company has a 69.12% share of overseas revenue, benefiting from the depreciation of the RMB [3]. - It has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong innovation capabilities and market share [3]. Stock Performance - On August 4, the stock price of Haitai New Light increased by 7.39%, with a trading volume of 203 million yuan and a market capitalization of 5.472 billion yuan [1]. - The average trading cost of the stock is 38.17 yuan, with the stock currently near a resistance level of 45.73 yuan, indicating potential for upward movement if this level is breached [6].